| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA924: Tirzepatide for treating type 2 diabetes |
|
Medicine details |
|
| Medicine name | tirzepatide (Mounjaro®) |
| Formulation | subcutaneous injection |
| Reference number | 4248 |
| Indication | Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications or in addition to other medicinal products for the treatment of diabetes. |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Endocrine system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 30/09/2022 |
| NICE guidance | |